SS-31, also known by its developmental name elamipretide and the research designation MTP-131, is a tetrapeptide that has attracted sustained interest in preclinical and early translational research for its capacity to selectively accumulate within the inner mitochondrial membrane. Its short sequence – D-Arg-dimethylTyr-Lys-Phe-NH₂ – encodes amphipathic properties that allow it to interact with cardiolipin, a phospholipid unique to the inner mitochondrial membrane. This specificity has made SS-31 a widely used probe in research models examining mitochondrial bioenergetics, oxidative stress, and cellular energy dynamics.
Note: SS-31 is a research compound. All information below pertains strictly to preclinical in vitro and in vivo studies. This article does not constitute medical advice, and SS-31 is not approved for human use outside of registered clinical investigations.
Cardiolipin Interaction: A Mechanistic Foundation
A foundational aspect of SS-31 research concerns its binding to cardiolipin. Cardiolipin is an essential structural component of the inner mitochondrial membrane and plays a direct role in stabilizing respiratory chain supercomplexes, particularly complexes I–IV. Under conditions of oxidative stress, cardiolipin can become oxidized, impairing supercomplex assembly and reducing electron transport chain (ETC) efficiency.
A seminal study by Birk et al. (2013), published in Cell Metabolism, demonstrated that SS-31 binds cardiolipin and prevents its oxidation by cytochrome c, thereby preserving mitochondrial cristae architecture and maintaining ETC supercomplex organization. The researchers found that SS-31-treated mitochondria in ischemia-reperfusion injury models showed significantly better preservation of membrane potential and ATP output compared to controls. This mechanistic work established a molecular rationale for SS-31’s observed effects in multiple model systems.
Ischemia-Reperfusion Models
Some of the most extensively published SS-31 research involves myocardial ischemia-reperfusion (IR) injury models. IR injury occurs when blood flow is restored after a period of oxygen deprivation, triggering a burst of reactive oxygen species (ROS) generation and mitochondrial permeability transition pore (mPTP) opening – events that can lead to cardiomyocyte death.
Szeto et al. (2014) and related preclinical work demonstrated that SS-31 administration in rodent models prior to or immediately following reperfusion significantly reduced infarct size. The proposed mechanism centers on SS-31’s ability to maintain cardiolipin integrity, which in turn stabilizes the adenine nucleotide translocator (ANT) – a component of the mPTP. By inhibiting mPTP opening, SS-31 appeared to reduce cytochrome c release and subsequent apoptotic cascades in cardiomyocytes in these animal models.
Importantly, research groups have also explored SS-31 in aged cardiac tissue. Studies using aged mouse hearts have found that mitochondrial respiration declines with age in parallel with cardiolipin content changes. SS-31 treatment in these aged animal models has been reported to restore state 3 mitochondrial respiration and improve maximal oxidative phosphorylation capacity, suggesting utility as a research tool in aging biology.
Renal Protective Models
Beyond cardiac research, SS-31 has been investigated in kidney-focused models. Acute kidney injury (AKI), particularly that induced by cisplatin or ischemia in animal models, involves significant mitochondrial damage within renal tubular cells. Bhargava and Schnellmann (2017) reviewed evidence indicating that mitochondrial fragmentation and biogenesis impairment represent core events in AKI.
In cisplatin-induced AKI mouse models, SS-31 administration was associated with reduced tubular cell apoptosis, preserved mitochondrial membrane potential, and lower serum creatinine elevations compared to untreated controls. Researchers attributed these findings to SS-31’s ability to reduce lipid peroxidation within proximal tubule cell mitochondria – an in vivo observation consistent with the compound’s cardiolipin-protective mechanism documented in vitro.
Skeletal Muscle and Bioenergetics Research
Mitochondrial dysfunction has been implicated in age-related skeletal muscle decline (sarcopenia), and SS-31 has been used as a research tool to probe this relationship. Siegel et al. (2013) reported that SS-31 treatment in aged mice improved skeletal muscle mitochondrial function, assessed by high-resolution respirometry. Maximum coupled respiration and electron transport capacity were both higher in SS-31-treated aged animals compared to vehicle controls, without significant changes observed in young animals – suggesting the compound’s effects may be more pronounced under conditions of existing mitochondrial impairment.
Further work examining SS-31 in muscle disuse atrophy models (hindlimb unloading) found that SS-31 attenuated the reduction in mitochondrial function typically observed after prolonged immobilization, providing a model for studying how mitochondrial protection may modulate disuse-related cellular changes.
Oxidative Stress and ROS Attenuation
A consistent theme across SS-31 research is attenuation of mitochondrial ROS production. Because SS-31 is concentrated at the inner mitochondrial membrane via its interaction with cardiolipin, it is positioned to scavenge ROS generated at complexes I and III of the ETC – the primary sites of superoxide generation during periods of metabolic stress.
In vitro studies using isolated mitochondria have documented reductions in H₂O₂ production following SS-31 exposure under conditions of complex I inhibition and elevated succinate concentrations – a model of the reversed electron transport that drives much of the burst ROS generation seen in IR injury. This mechanistic data has helped researchers understand why ROS attenuation appears to be downstream of, rather than independent from, the cardiolipin-binding effect.
Structural Integrity and Research Sourcing Considerations
For in vitro and in vivo research applications, SS-31 is typically supplied as a lyophilized acetate or trifluoroacetate salt, reconstituted in sterile water or saline. Published studies have used concentrations ranging widely depending on the model system, with dosing in animal studies not translatable to human use.
Researchers sourcing SS-31 for preclinical use should prioritize vendors who provide mass spectrometry-confirmed identity, HPLC purity documentation (≥98% is commonly cited in peer-reviewed methods sections), and endotoxin testing results. Because SS-31’s small size (molecular weight ~639 Da) makes it susceptible to mis-synthesis or truncation, sequence verification data is essential for replication of published results.
Institutions requiring custom synthesis for ongoing research should request independent third-party testing rather than relying solely on in-house vendor certificates, consistent with good research practice guidelines.
Summary
SS-31 (elamipretide) remains one of the most mechanistically well-characterized peptide tools in mitochondria-focused research. Its selective accumulation at the inner mitochondrial membrane via cardiolipin binding, combined with demonstrated effects on ETC supercomplex stability, mPTP dynamics, and ROS attenuation across multiple preclinical model systems, makes it a high-utility compound for researchers studying mitochondrial bioenergetics, ischemia-reperfusion biology, aging models, and metabolic dysfunction. All research applications should be conducted under appropriate institutional oversight and are not intended to represent clinical or therapeutic claims.
Key References
- Birk AV et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250–1261.
- Szeto HH. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029–2050.
- Siegel MP et al. (2013). Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell, 12(5), 763–771.
- Bhargava P, Schnellmann RG. (2017). Mitochondrial energetics in the kidney. Nature Reviews Nephrology, 13(10), 629–646.
